Skip to content
Screener

Mesa Laboratories MLAB Q4 2026 Annual earnings

Reported May 27, 2026 · Before market open

Revenue$63.7MMiss by $1.5M
EPS$2.76Beat by $0.67
Revenue estimate$65.2M
EPS estimate$2.09

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$61.6M
EPS estimate$1.59

Financials

Q4 2026

Income statement

See full
Revenue$63.7M+2.6%

Balance sheet

See full
Cash & equivalents$26.9M-1.4%
Total debt$78.7M-53.1%
Total equity$186.2M+16.5%
Total assets$427.7M-1.3%

Cash flow

See full
Operating cash flow$14.0M+10.2%
CapEx$417.0K-44.9%
Free cash flow$13.5M+13.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$488.5M-24.2%
Enterprise value$540.28M-31.2%
P/S2×-0.7×

Profitability

See full
FCF margin15.9%-1.8pp

Returns & leverage

See full
Debt / equity0.4×-0.6×
Current ratio1.7×+1.1×

Segments

By geography

See full
US$30.1M-3.7%
Other$29.6M+14.3%
CN$4.1M-19.5%

By segment

See full
Clinical Genomics$12.2M+5.8%
Biopharmaceutical Development$8.8M-29.9%

FAQ

When did Mesa Laboratories report Q4 2026 earnings?
Mesa Laboratories (MLAB) reported Q4 2026 earnings on May 27, 2026 before market open.
What were Mesa Laboratories's Q4 2026 revenue and EPS?
Mesa Laboratories reported revenue of $63.7M and eps of $2.76 for Q4 2026.
Did Mesa Laboratories beat estimates in Q4 2026?
Revenue missed the consensus estimate of $65.2M by $1.5M. EPS beat the consensus estimate of $2.09 by $0.67.
How did Mesa Laboratories's Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.6% from $62.1M a year earlier and eps grew 23.8% from $2.23.
Where can I find Mesa Laboratories's Q4 2026 SEC filings?
You can read the 8-K earnings release (0000724004-26-000039) and the 10-K periodic report (0000724004-26-000047) directly on SEC EDGAR. The filing index links above go to sec.gov.